ArticleScience advances2023
CD34
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Cellular crosstalk of fibroblast-myofibroblast transition in intestinal homeostasis and disease.Biomarker research · 2026Review
- GNPs-pIL-4 reprograms macrophage polarization and activates the OSM/GSNOR/ENG axis to improve angiogenesis in ischemic limbs.Science advances · 2026Article
- Foxs1-mediated transformation of CD34EMBO molecular medicine · 2026Article
- Liver Kinase B1 in CD11cAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Perivascular adipose single-cell atlas identifies CD55Nature communications · 2026Article
- HIF1A transcriptionally activates CDKN1A to drive ferroptosis in skeletal muscle ischaemia-reperfusion injury.Journal of orthopaedic translation · 2026Article
- A Hypoxia Associated STC2 High Endothelial Subpopulation is Linked to Lipid Metabolic Reprogramming, Pathological Angiogenesis, and Immune Remodeling in Head and Neck Squamous Cell Carcinoma.International journal of general medicine · 2026Article
- FMO2 Promotes Angiogenesis via Regulation of N-Acetylornithine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Bio-Membrane-Based Nanofiber Scaffolds: Targeted and Controlled Carriers for Drug Delivery-An Experimental In Vivo Study.Biomimetics (Basel, Switzerland) · 2025Article
- Modeling tumor relapse using proliferation tracing and ablation transgenic mouse.NPJ breast cancer · 2025Article
- Dynamic Changes of Immunoreactive CD34, CD117, and CD41 Hematopoietic Stem Cells in Human Placentas of Different Gestational Ages.Journal of developmental biology · 2025Article
- IL-33-Induced TREM2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Deep topic modeling of spatial transcriptomics in the rheumatoid arthritis synovium identifies distinct classes of ectopic lymphoid structures.bioRxiv : the preprint server for biology · 2025Article
- The Dual Role of Cellular Senescence in Macrophages: Unveiling the Hidden Driver of Age-Related Inflammation in Kidney Disease.International journal of biological sciences · 2025Review
- Review
- Modulation of anti-cardiac fibrosis immune responses by changing M2 macrophages into M1 macrophages.Molecular medicine (Cambridge, Mass.) · 2024Article
- Neutrophil extracellular traps promoting fibroblast activation and aggravating limb ischemia through Wnt5a pathway.American journal of cancer research · 2024Article
- Macrophage phenotypes and functions: resolving inflammation and restoring homeostasis.Trends in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.